|
1
|
Leung WK, Wu MS, Kakugawa Y, et al:
Screening for gastric cancer in Asia: current evidence and
practice. Lancet Oncol. 9:279–287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Macdonald JS: Treatment of localized
gastric cancer. Semin Oncol. 31:566–573. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carrato A, Gallego-Plazas J and
Guillen-Ponce C: Adjuvant therapy of resected gastric cancer is
necessary. Semin Oncol. 32:S105–S108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chipponi J, Huguier M, Pezet D, et al:
Randomized trial of adjuvant chemotherapy after curative resection
for gastric cancer. Am J Surg. 187:440–445. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Topuz E, Basaran M, Saip P, et al:
Adjuvant intraperitoneal chemotherapy with cisplatinum,
mitoxantrone, 5-fluorouracil, and calcium folinate in patients with
gastric cancer: a phase II study. Am J Clin Oncol. 25:619–624.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mamenta EL, Poma EE, Kaufmann WK,
Delmastro DA, Grady HL and Chaney SG: Enhanced replicative bypass
of platinum-DNA adducts in cisplatin-resistant human ovarian
carcinoma cell lines. Cancer Res. 54:3500–3505. 1994.PubMed/NCBI
|
|
8
|
Extra JM, Espie M, Calvo F, Ferme C,
Mignot L and Marty M: Phase I study of oxaliplatin in patients with
advanced cancer. Cancer Chemother Pharmacol. 25:299–303. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Louvet C, André T, Tigaud JM, et al: Phase
II study of oxaliplatin, fluorouracil, and folinic acid in locally
advanced or metastatic gastric cancer patients. J Clin Oncol.
20:4543–4548. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
De Vita F, Orditura M, Matano E, et al: A
phase II study of biweekly oxaliplatin plus infusional
5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment
of advanced gastric cancer patients. Br J Cancer. 92:1644–1649.
2005.PubMed/NCBI
|
|
11
|
Al-Batran SE, Atmaca A, Hegewisch-Becker
S, et al: Phase II trial of biweekly infusional fluorouracil,
folinic acid, and oxaliplatin in patients with advanced gastric
cancer. J Clin Oncol. 22:658–663. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lordick F, Lorenzen S, Stollfuss J, et al:
Phase II study of weekly oxaliplatin plus infusional fluorouracil
and folinic acid (FUFOX regimen) as first-line treatment in
metastatic gastric cancer. Br J Cancer. 93:190–194. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cavanna L, Artioli F, Codignola C, et al:
Oxaliplatin in combination with 5-fluorouracil (5-FU) and
leucovorin (LV) in patients with metastatic gastric cancer (MGC).
Am J Clin Oncol. 29:371–375. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wei Q, Frazier ML and Levin B: DNA repair:
a double-edged sword. J Natl Cancer Inst. 92:440–441. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Woynarowski JM, Faivre S, Herzig MC, et
al: Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol.
58:920–927. 2000.PubMed/NCBI
|
|
16
|
Reed E: ERCC1 and clinical resistance to
platinum-based therapy. Clin Cancer Res. 11:6100–6102. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nuñez F, Chipchase MD, Clarke AR and
Melton DW: Nucleotide excision repair gene (ERCC1) deficiency
causes G(2) arrest in hepatocytes and a reduction in liver
binucleation: the role of p53 and p21. FASEB J. 14:1073–1082.
2000.PubMed/NCBI
|
|
18
|
Cobo M, Isla D, Massuti B, et al:
Customizing cisplatin based on quantitative excision repair
cross-complementing 1 mRNA expression: a phase III trial in
non-small-cell lung cancer. J Clin Oncol. 25:2747–2754. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Olaussen KA, Dunant A, Fouret P, et al:
DNA repair by ERCC1 in non-small-cell lung cancer and
cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weberpals J, Garbuio K, O’Brien A, et al:
The DNA repair proteins BRCA1 and ERCC1 as predictive markers in
sporadic ovarian cancer. Int J Cancer. 124:806–815. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Denlinger CS and Cohen SJ: Progress in the
development of prognostic and predictive markers for
gastrointestinal malignancies. Curr Treat Options Oncol. 8:339–351.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iqbal S, Stoehlmacher J and Lenz HJ:
Tailored chemotherapy for colorectal cancer: a new approach to
therapy. Cancer Invest. 22:762–773. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Höfler H, Langer R, Ott K and Keller G:
Prediction of response to neoadjuvant chemotherapy in carcinomas of
the upper gastrointestinal tract. Adv Exp Med Biol. 587:115–120.
2006.
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Boku N: Perspectives for personalization
in chemotherapy of advanced gastric cancer. Discov Med. 9:84–89.
2010.PubMed/NCBI
|
|
26
|
Mauer AM, Kraut EH, Krauss SA, et al:
Phase II trial of oxaliplatin, leucovorin and fluorouracil in
patients with advanced carcinoma of the esophagus. Ann Oncol.
16:1320–1325. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Suo Z, Lippard SJ and Johnson KA: Single
d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA
polymerization. Biochemistry. 38:715–726. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Selvakumaran M, Pisarcik DA, Bao R, Yeung
AT and Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing
the nucleotide excision repair pathway in ovarian cancer cell
lines. Cancer Res. 63:1311–1316. 2003.PubMed/NCBI
|
|
29
|
Sun JM, Ahn MJ, Park MJ, et al: Expression
of excision repair cross-complementation group 1 as predictive
marker for nasopharyngeal cancer treated with concurrent
chemoradiotherapy. Int J Radiat Oncol Biol Phys. 80:655–660. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hwang IG, Ahn MJ, Park BB, et al: ERCC1
expression as a prognostic marker in N2(+) nonsmall-cell lung
cancer patients treated with platinum-based neoadjuvant concurrent
chemoradiotherapy. Cancer. 113:1379–1386. 2008.
|
|
31
|
Jun HJ, Ahn MJ, Kim HS, et al: ERCC1
expression as a predictive marker of squamous cell carcinoma of the
head and neck treated with cisplatin-based concurrent
chemoradiation. Br J Cancer. 99:167–172. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kwon HC, Roh MS, Oh SY, et al: Prognostic
value of expression of ERCC1, thymidylate synthase, and glutathione
S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in
advanced gastric cancer. Ann Oncol. 18:504–509. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim MK, Cho KJ, Kwon GY, et al: ERCC1
predicting chemoradiation resistance and poor outcome in
oesophageal cancer. Eur J Cancer. 44:54–60. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang IY, Kim MH, Kim HB, et al: Small
interfering RNA-induced suppression of ERCC1 enhances sensitivity
of human cancer cells to cisplatin. Biochem Biophys Res Commun.
327:225–233. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song L, Ritchie AM, McNeil EM, Li W and
Melton DW: Identification of DNA repair gene Ercc1 as a novel
target in melanoma. Pigment Cell Melanoma Res. 24:966–971. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sancar A: Excision repair in mammalian
cells. J Biol Chem. 270:15915–15918. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Darcy KM, Tian C and Reed E: A Gynecologic
Oncology Group study of platinum-DNA adducts and excision repair
cross-complementation group 1 expression in optimal, stage III
epithelial ovarian cancer treated with platinum-taxane
chemotherapy. Cancer Res. 67:4474–4481. 2007. View Article : Google Scholar
|
|
38
|
Kudo K, Gavin E, Das S, Amable L, Shevde
LA and Reed E: Inhibition of Gli1 results in altered c-Jun
activation, inhibition of cisplatin-induced upregulation of ERCC1,
XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Oncogene. 31:4718–4724. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wei J, Zou Z, Qian X, et al: ERCC1 mRNA
levels and survival of advanced gastric cancer patients treated
with a modified FOLFOX regimen. Br J Cancer. 98:1398–1402. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Matsubara J, Nishina T, Yamada Y, et al:
Impacts of excision repair cross-complementing gene 1 (ERCC1),
dihydropyrimidine dehydrogenase, and epidermal growth factor
receptor on the outcomes of patients with advanced gastric cancer.
Br J Cancer. 98:832–839. 2008. View Article : Google Scholar
|
|
41
|
Kim JS, Kim MA, Kim TM, et al: Biomarker
analysis in stage III–IV (M0) gastric cancer patients who received
curative surgery followed by adjuvant 5-fluorouracil and cisplatin
chemotherapy: epidermal growth factor receptor (EGFR) associated
with favourable survival. Br J Cancer. 100:732–738. 2009.
|
|
42
|
Napieralski R, Ott K, Kremer M, et al:
Combined GADD45A and thymidine phosphorylase expression levels
predict response and survival of neoadjuvant-treated gastric cancer
patients. Clin Cancer Res. 11:3025–3031. 2005. View Article : Google Scholar
|
